-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-520218-23-00
10
Pulmonary Arterial Hypertension
-
2025-522586-30-00
5
Psoriatic Arthritis
-
2025-523259-72-00
5
Hidradenitis Suppurativa (HS)
-
2025-523425-17-00
4
Proteinuric kidney diseases
-
2024-520446-31-00
5
2026-05-27
Participants with overweight or obesity, and type 2 diabetes
-
2024-517943-29-00
5
2026-04-21
Pulmonary Hypertension associated with interstitial lung disease (WHO
-
2025-522191-86-00
5
2026-04-02
Focal segmental glomerulosclerosis
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2023-509207-33-01
9
2025-07-09
Early acute spinal cord injury
-
2024-514732-24-00
6
2025-04-28
Juvenile idiopathic arthritis
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2023-507129-40-00
4
2024-08-06
interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
-
2022-501099-24-00
5
2023-12-22
Migraine
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2023-509138-21-00
5
2021-08-26
Pulmonary Arterial Hypertension (PAH)
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2024-517614-14-00
4
2025-11-28
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-513613-12-00
9
2025-09-18
Part A: Healthy volunteers (Part A is not applicable to the EU; for in
-
2024-519521-37-01
10
2025-07-30
Acute ischemic stroke
-
2024-519059-28-00
5
2025-07-17
Chronic Heart Failure